Appendix 1—table 3. Pharmacokinetic-pharmacodynamic linear regression analysis.
| Viral outcome measurement vs. | Sofosbuvir AUClast | GS-331007 AUClast | Daclatasvir AUClast | |||
|---|---|---|---|---|---|---|
| Slope (95% CI) | p | Slope (95% CI) | p | Slope (95% CI) | p-value | |
| Area under the viral load-time curve | –157 (−423–109) |
0.239 | 16.2 (−74.4–107) |
0.719 | –14.2 (−67.1–38.6) |
0.589 |
| Viral elimination half-life | 1.55×10–4 (–8.70×10–4 - 5.60×10–4) |
0.662 | –3.64×10–5 (–2.74×10–4 - 2.01×10–4) |
0.757 | 2.17×10–5 (–1.16×10–4 - 1.60×10–4) |
0.751 |
| Relative reduction in viral load at day 1 | 1.31×10–6 (–4.54×10–6 - 7.16×10–6) |
0.652 | 2.67×10–8 (–1.94×10–6 - 1.99×10–6) |
0.978 | 2.81×10–7 (–8.62×10–7 - 1.42×10–6) |
0.621 |
| Relative reduction in viral load at day 7 | 2.53×10–7 (–2.81×10–7 - 7.86×10–7) |
0.343 | 5.09×10–8 (–1.29×10–7 - 2.31×10–7) |
0.569 | 1.44*10–8 (–9.11×10–8 - 1.20×10–7) |
0.783 |
95%CI is the 95% confidence interval around the slop.